United States Heparin Market Insights Forecasts to 2033
- The United States Heparin Market Size was valued at USD 1.19 Billion in 2023.
- The Market Size is Growing at a CAGR of 6.34% from 2022 to 2033.
- The United States Heparin Market Size is Expected to Reach USD 2.20 Billion by 2033.
Get more details on this report -
The United States Heparin Market Size is Expected to Reach USD 2.20 Billion by 2033, at a CAGR of 6.34% during the forecast period 2023 to 2033.
Heparin is an anticoagulant medication commonly used to prevent and treat blood clots. Heparin is a common anticoagulant injection that is also known as ordinary heparin or unfractionated heparin (UFH). Heparin is sold under the brand Hep-Lock. It works by preventing the formation of blood clots in the body and is typically administered via injection. Heparin is widely used in a variety of medical settings, such as hospitals, clinics, and at-home care. Heparin is a medication that prevents blood clots from forming in people who have certain medical conditions or are undergoing medical procedures that increase the risk of blood clot formation, such as surgery. Heparin injection thins the blood. It is used to decrease blood clotting ability and to help prevent dangerous clots from forming in blood arteries.
This research report categorizes the market for the United States heparin market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States heparin market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United States heparin market.
United States Heparin Market Report Coverage
|Market Size in 2023:
|USD 1.19 Billion
|Forecast Period 2023-2033 CAGR:
|2033 Value Projection:
|USD 2.20 Billion
|Historical Data for:
|No. of Pages:
|Tables, Charts & Figures:
|By Type, By Application
|Baxter International Inc., Pfizer Inc., Sagent Pharmaceuticals, Mylan N.V., Bayer AG, B. Braun Melsungen AG, Scientific Protein Laboratories LLC, Sanofi S.A, Merck & Co. Inc, Meitheal Pharmaceuticals, Leo Pharma A/S, Nanjing King-Friend Biochemical Pharmaceutical, Amphastar Pharmaceuticals, Shenzhen Hepalink and Other Key Vendors.
|Pitfalls & Challenges:
|COVID-19 Empact,Challenges, Future, Growth, & Analysis
Get more details on this report -
The rising prevalence of chronic diseases is one of the major factors driving the heparin market, as is the rising prevalence of coagulation disorders such as venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism. Heparin can influence cancer cell angiogenesis, proliferation, migration, and invasion through a variety of mechanisms. The high cancer burden is expected to drive heparin market growth in the United States.
The primary factors limiting market growth are the side effects of heparin. The most common side effect of heparin is bleeding. Heparin can cause spontaneous bleeding from open wounds or surgical sites, the intestines and stomach, the ovaries and uterus, and the mouth and gums. These side effects can hinder market growth during the forecast period.
- In 2023, the low molecular weight heparin segment accounted for the largest revenue share over the forecast period.
Based on the type, the United States heparin market is segmented into low molecular-weight heparin and ultra-low molecular weight heparin. Among these, the low molecular weight heparin segment has the largest revenue share over the forecast period. The segment's dominance can be attributed to the high rate of product acceptance in developed markets and the superior safety profiles of these goods when compared to competitors. Fragmin (Dalteparin sodium), Lovenox (Enoxaparin sodium), and Innohep are three important LMWH (Tinzaparin sodium) medications. Several industry participants are also focusing on the development and introduction of new LMWH products to the market.
- In 2023, the deep vein thrombosis (DVT) segment accounted for a significant revenue share over the forecast period.
Based on application, the United States heparin market is segmented into atrial fibrillation and heart attack, stroke, deep vein thrombosis (DVT), and Others. Among these, the deep vein thrombosis (DVT) segment has a significant revenue share over the forecast period. A deep-vein thrombosis (DVT) is a blood clot that forms within the deep veins of the arms, as well as the mesenteric and cerebral veins. The exact number of people infected with deep vein thrombosis was unknown as of 2020, according to the Centers for Disease Control and Prevention (CDC), though people were expected to be affected each year in the United States. According to the Centers for Disease Control. Thus, the rising prevalence of deep vein thrombosis is expected to drive demand for heparin-based products, boosting market growth over the forecast period.
The report offers the appropriate analysis of the key organizations/companies involved within the United States heparin market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Baxter International Inc.
- Pfizer Inc.
- Sagent Pharmaceuticals
- Mylan N.V.
- Bayer AG
- B. Braun Melsungen AG
- Scientific Protein Laboratories LLC
- Sanofi S.A
- Merck & Co. Inc
- Meitheal Pharmaceuticals
- Leo Pharma A/S
- Nanjing King-Friend Biochemical Pharmaceutical
- Amphastar Pharmaceuticals
- Shenzhen Hepalink
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In June 2021, Janssen Research & Development, LLC, a Bayers development partner, submitted an NDA to the US Food and Drug Administration (USFDA) for the use of the oral anticoagulant Xarelto (rivaroxaban) in pediatric patients for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years of age after at least 5 days of initial parenteral anticoagulant treatment.
This study forecasts revenue at regional, and country levels from 2023 to 2033. Spherical Insights has segmented the United States Heparin Market based on the below-mentioned segments:
United States Heparin Market, By Type
- Low Molecular Weight Heparin
- Ultra-low Molecular Weight Heparin
United States Heparin Market, By Application
- Atrial Fibrillation and Heart Attack
- Deep Vein Thrombosis (DVT)
Need help to buy this report?